## AB-NK205 RAFA-CT (RafA-4) Antibody

**Target Protein** 

Pan-specific polyclonal antibody for monitoring the expression of human protein-serine/threonine kinase Raf-A (ARaf)



Email: info@kinexus.ca

Phone: 604-323-2547

Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Name Long:	A-Raf proto-oncogene serine/threonine-protein kinase
Alias:	ARAF; A-RAF; ARAF1; A-raf-1; Kinase A-Raf; PKS; PKS2; Proto-oncogene Pks; V-raf murine sarcoma 3611 viral oncogene; RP1-230G1.1-005; RP1-230G1_1; A6NIT1; B4DMG5; Q5H9B2; Q96II5ENSG00000078061
UniProt ID:	P10398
Sequence Predicted Mass (KDa):	67.585 (606 AA; P10398); 20.904 (186 AA; P10398-2)
Observed SDS-PAGE Mass (KDa):	63-70
Immunogen	
Antibody Immunogen Source:	Human Raf-A (ARaf) sequence peptide
Antibody Immunogen Sequence:	PSLHRTQADELPAC
Location in Target:	Corresponds to amino acid residues P584 to C597; C-terminus
Peptide Type:	For pan-specific recognition of target expression levels.
Target Phosphosite:	Not phosphorylated
Production	
Antibody Host Species:	Rabbit
Antibody Type:	Polyclonal
Antibody Ig Isotype Clone Lot:	Immunoglobulin G
Antibody Ig Isotype Clone Lot: Production Method:	The immunoglobulin G The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
	The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution
Production Method:	The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Production Method: Antibody Amount:	The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 µg
Production Method: Antibody Amount: Antibody Concentration:	The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 $\mu$ g 0.25 mg/ml
Production Method: Antibody Amount: Antibody Concentration: Lot Number:	The immunizing peptide was produced on an A.B.I. automated peptide synthesizer. The peptide was cleaved from the synthesis resin with HF and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by amino acid analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. 25 µg 0.25 mg/ml 10320

## AB-NK205 RAFA-CT (RafA-4) Antibody



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Applications	
Product Use:	Western blotting   Antibody microarrays
Antibody Dilution Recommended:	2 µg/ml for immunoblotting
Antibody Species Reactivity:	Human, mouse, rat and many other mammals
Detection by Immunoblotting in Cell/Tissue Lysates:	Medium immunoreactivity with atarget-sized protein in rat pheochromocytoma (PC12) cells.

This product is for in vitro research use only and is not intended for use in humans or animals.

For more information on our products please visit <u>www.kinexusproducts.ca</u> or contact us at 1-866-KINEXUS(546-3987)